Connect with us

Technology

Callio Therapeutics Launches with US$187 Million Series A to Advance Multi-Payload Antibody-Drug Conjugate Platform Through Clinical Proof-of-Concept

Published

on

Frazier Life Sciences launches Callio Therapeutics based on multi-payload antibody-drug conjugate technology and programs exclusively in-licensed from Singapore-based Hummingbird BioscienceFinancing led by Frazier Life Sciences with significant participation from Jeito Capital alongside other life sciences investors including Novo Holdings A/S, Omega Funds, ClavystBio, Platanus, Norwest, Pureos Bioventures, SEEDS Capital and EDBICompany to advance innovative multi-payload programs designed to maximize therapeutic benefit for cancer patients by overcoming limitations of existing single-payload therapies

SEATTLE and SINGAPORE, March 3, 2025 /PRNewswire/ — Callio Therapeutics, a biotechnology company focused on realizing the promise of multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy, today announced its launch with the closing of a $187.0 million Series A financing round. This financing was led by Frazier Life Sciences with significant participation from Jeito Capital alongside other life sciences investors, including Novo Holdings A/S, Omega Funds, ClavystBio, Platanus, Norwest, Pureos Bioventures, SEEDS Capital and EDBI. The newly formed company, with headquarters in Seattle and Singapore, intends to use the proceeds from the Series A financing to achieve clinical proof-of-concept for its HER2-targeted dual-payload ADC and a second undisclosed ADC program.

In conjunction with the financing, Callio Therapeutics has entered into an exclusive worldwide license agreement with Hummingbird Bioscience for its multi-payload ADC platform in oncology, and associated intellectual property and pipeline assets, in exchange for equity, potential milestone payments and royalties.

“We are delighted to be launching Callio Therapeutics with the support of Frazier Life Sciences and this syndicate of investors. Multi-payload ADCs have the potential to enable the targeted delivery of rational drug combinations to cancer cells, and may provide significantly enhanced efficacy,” said Piers Ingram, PhD, co-founder and Chief Executive Officer of Callio Therapeutics. “This new generation of ADC therapies may meaningfully improve outcomes for patients.”  

Leadership Team

The founding Callio Therapeutics management team comprises individuals with extensive experience from leading biotechnology and biopharmaceutical companies including ProfoundBio, Silverback Therapeutics, SeaGen, Medarex, Hummingbird Bioscience and Genentech:

Piers Ingram, PhD, Chief Executive OfficerJerome Boyd-Kirkup, PhD, Chief Scientific OfficerNaomi Hunder, MD, Chief Medical OfficerAngèle Maki, PhD, Chief Business Officer

“The multi-payload ADCs being developed at Callio Therapeutics have the potential to address large unmet medical needs by overcoming many of the limitations of existing ADCs,” said Adam Simpson, Executive Board Chair of Callio Therapeutics and Venture Partner at Frazier Life Sciences. “With the expertise of the Callio Therapeutics team, together with access to the innovative multi-payload ADC technology, we believe that Callio Therapeutics will be the first company to show the clinical benefit of this exciting new multi-payload ADC approach and is well positioned to transform cancer therapy.”

About Callio Therapeutics
Headquartered in Seattle and Singapore, Callio Therapeutics is focused on realizing the promise of multi-payload antibody-drug conjugates to transform cancer patient outcomes. The company is developing next-generation, multi-payload antibody-drug conjugates (ADCs) that feature differentiated payload and linker technologies that enable targeted delivery of multi agents to tumor cells to maximize therapeutic benefit. Callio Therapeutics’ lead program is a HER2-targeted dual-payload ADC. Callio Therapeutics was created by Frazier Life Sciences, a longstanding investment firm focused on innovative therapeutics, based on ADC technology and programs exclusively in-licensed from Hummingbird Bioscience. For more information, please visit www.calliotx.com and follow Callio Therapeutics on LinkedIn.

About Frazier Life Sciences
Frazier Life Sciences invests globally in private and publicly traded companies that discover, develop, and commercialize innovative biopharmaceuticals. Frazier Life Sciences manages over $3.9 billion in capital, including Venture Funds focusing on company creation and private companies and the long-only Public Fund focused on small and mid-cap public companies. Since 2005, over 60 Frazier Life Sciences portfolio companies, many of which were created or seeded by Frazier Life Sciences, have completed IPOs or M&As. The Frazier Life Sciences team consists of over 40 professionals with deep expertise in biopharmaceuticals, primarily located in Palo Alto, Calif. (headquarters), San Diego, Seattle, Boston, New York and London. For more information about Frazier Life Sciences, please visit frazierls.com and follow on LinkedIn.

About Hummingbird Bioscience
Hummingbird Bioscience is a Singapore-based biotherapeutics company working at the interface of artificial intelligence and human innovation to discover and develop transformative medicines for hard-to-treat diseases. Hummingbird Bioscience’s computational and systems biology technologies have generated a pipeline of innovative clinical-stage monoclonal antibodies and antibody-drug conjugates in oncology and autoimmunity.  At Hummingbird Bioscience, the commitment to rigorous science, teamwork, and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic. For more information, please visit www.hummingbirdbioscience.com, and follow Hummingbird Bioscience on LinkedIn, X (formerly Twitter), and YouTube.

Logo – https://mma.prnewswire.com/media/2629713/Callio_Therapeutics_Logo.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/callio-therapeutics-launches-with-us187-million-series-a-to-advance-multi-payload-antibody-drug-conjugate-platform-through-clinical-proof-of-concept-302388240.html

Continue Reading

Technology

Wenge AI launches enterprise decision AI seminar series in Shenzhen

Published

on

By

SHENZHEN, China, Oct. 23, 2026 /PRNewswire/ — Wenge AI brought together more than 50 academics, industry experts and business leaders from the Greater Bay Area for the first session of its seminar series on putting decision AI into practice in enterprises. Participants explored how AI is being applied to management decisions, risk anticipation and business analysis.

Decision-making becomes a new frontier for AI

In his opening remarks, Professor Liu Min, a director at The Chinese University of Hong Kong (CUHK) Business School, said AI was rewriting the fundamental rules of business competition. Managers should test its effectiveness in real operating environments rather than simply observe its development, he said. He welcomed Wenge AI’s sustained investment in decision AI and expressed hope that Chinese AI companies would translate their technological capabilities into productivity gains for society.

Hang Tian, director of CUHK’s Asian Institute of Supply Chains & Logistics, outlined the institute’s latest AI research. He said the institute had long used AI to translate research into practical applications. A macro-event analysis system developed by his team is supporting the deployment of logistics agents for warehousing, transport capacity and compliance. He looked forward to working with Wenge AI to support Chinese companies expanding overseas and using AI to strengthen the real economy, turning research findings into workflows that businesses can put into operation.

Wenge AI chairman Wang Lei said general-purpose large language models still faced limitations in enterprise decisions involving multiple stakeholders, complex reasoning and rapidly changing conditions. Decision AI would move beyond answering questions to simulating future scenarios, he said. Wenge AI has built the Decitron Decision Engine, which is the world’s first general-purpose large decision model, alongside its Decision Intelligence Platform (DIP) to support decision-making in real business operations.

Enterprises move from AI exploration to implementation

Xu Huansheng, vice-president of Meinian Health Group, spoke on “AI-driven transformation in the healthcare industry: decision-making, operations and growth”. He said AI was now essential for businesses. Markets would value companies for their future capabilities rather than pay a premium for past achievements.

Meinian Health Group has pursued an AI transformation since 2021, Xu Huansheng said. The quality of AI-assisted decisions depends on the completeness and continuity of data. In healthcare, AI can deliver meaningful insights when imaging data, blood test results, genetic data and other information are connected and accumulated consistently over time. Meinian has been progressively embedding AI capabilities into its day-to-day operations.

Wenge AI vice-president Zhang Xina presented the case of a Fortune Global 500 new energy company that previously spent several days manually reconciling tens of thousands of purchase orders. After adopting Wenge AI’s DIP and large decision model, the company created a digital twin of its procurement workflow using data from its enterprise resource planning (ERP) system. Materials planners now use a single consolidated view to complete the work in about 10 minutes each day.

The system also identifies the causes of delivery problems. When the company’s on-time delivery rate fell by about 25 percentage points month on month, the AI identified incomplete shipments after dispatch, rather than slow dispatch, as the root cause. One supplier was delivering an average of 83 days late.

Frank, a veteran chief information officer, shared an enterprise perspective in his presentation on “Best practices for enterprise AI agents”. His team initially invested in integrated AI appliances and an internal AI platform to improve efficiency, but employees sometimes found that using them created additional work. His company has now embedded an AI ontology into the sales, planning and materials modules of its ERP system. The system directly handles demand forecasting, anomaly detection and order processing, with audit trails to ensure traceability. He said AI’s value should be demonstrated through the redesign of real business workflows.

Embedding AI into enterprise decision-making requires effective data governance, process redesign and validation in real business operations. Wenge AI develops general-purpose large decision models and enterprise platforms to help businesses turn AI capabilities into tangible value.

 

View original content:https://www.prnewswire.com/apac/news-releases/wenge-ai-launches-enterprise-decision-ai-seminar-series-in-shenzhen-302917913.html

SOURCE Wenge AI

Continue Reading

Technology

Superteam Wheels Launches Premium Cycling Brand MATIC, Unveils Flagship S68 Carbon Wheelset

Published

on

By

NEW YORK, Oct. 23, 2026 /PRNewswire/ — Superteam Wheels is proud to announce MATIC, its new premium sub‑brand, alongside the debut of MATIC S68, its flagship one‑piece carbon wheel set. Marking Superteam Wheels’ strategic expansion into high‑end road cycling gear, MATIC targets performance‑driven cycling enthusiasts, amateur racers and hardcore riders.

Inspired by the suffix “‑MATIC”, meaning precise mechanical motion, MATIC centers on craftsmanship, speed and lightweight performance. Drawing on Superteam Wheels’ long‑standing manufacturing expertise, the brand sets new benchmarks for premium cycling components.

The MATIC S68 features a 68 mm rim depth, 28 mm outer width and 21 mm inner width. The wheelset weighs 1,348 grams in total, comprising a 632-gram front wheel and a 716-gram rear wheel. Both wheels use 16 spokes.

Unlike common split‑molded one‑piece wheels on the market, MATIC S68 adopts high‑difficulty one‑piece molding and hole‑less rim technology for superior riding integration. Tuned iteratively based on real‑world testing by pro riders, it delivers consistent, powerful race‑ready performance.

Priced at US$2,999, the MATIC S68 offers strong value vs competing one‑piece wheels. A limited‑time promotion starts Oct 25 at US$2,599 (US$400 off). Buyers receive complimentary lifetime after-sales support to ease one piece wheel maintenance concerns.

Chris Zeng, Overseas Business Manager at Superteam Wheels, commented: “The MATIC S68 is the result of extensive development, iterations and rigorous testing. We want more performance-focused riders to experience premium flagship wheels, and we believe the MATIC S68 will meet their expectations.”

About Superteam Wheels

Founded in 2015, Superteam Wheels develops and manufactures high‑performance carbon wheels for road and gravel bikes. Built on race‑grade standards, its products are sold worldwide.

More info: https://superteamwheels.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/superteam-wheels-launches-premium-cycling-brand-matic-unveils-flagship-s68-carbon-wheelset-302917917.html

SOURCE Superteam Wheels

Continue Reading

Technology

Tradewind Finance Provides EUR 2 Million Export Factoring Facility to Eldohm to Support International Growth

Published

on

By

The tailored factoring facility enables Eldohm to offer international customers payment terms of up to 120 days while maintaining the liquidity needed to pay suppliers in China earlier in the trade cycle.

MÖNCHENGLADBACH, Germany, Oct. 23, 2026 /CNW/ — Tradewind Finance has provided a EUR 2 million export factoring facility, available in both euros and US dollars, to the Hong Kong subsidiary of Eldohm, a Netherlands-based international trading company. Arranged in collaboration with CRDT, the facility supports Eldohm’s international growth by providing working capital against outstanding invoices, enabling the company to manage larger orders and pursue further expansion in the United States.

Supporting Growth Across International Trade Flows

For internationally operating trading companies, managing the time between supplier payments and customer collections is a critical working capital challenge. Customers often require extended payment terms, while suppliers need to be paid much earlier in the trade cycle.

Eldohm’s Hong Kong subsidiary manages sourcing, product development and quality control, while the group’s financial administration is handled from the Netherlands. The company offers international customers payment terms of up to 120 days and can pay its suppliers in China earlier in the trade cycle.

As trading volumes grow, so does the amount of working capital required to bridge these payment cycles. This additional financing capacity enables Eldohm to accept larger orders, support growing customer demand and continue expanding its business in the United States.

An Export Factoring Solution Tailored to Eldohm

Tradewind structured the export factoring facility around Eldohm’s international trading operations.

By financing eligible export receivables issued by the Hong Kong entity, Tradewind makes working capital available before customers settle their invoices. This allows Eldohm to meet supplier payment obligations while continuing to offer competitive payment terms to its international customers.

The transaction required experience in international factoring, particularly in financing a Hong Kong entity with concentrated receivables exposure to a US-based buyer. These characteristics had made conventional financing through Dutch providers difficult to arrange.

Tradewind’s international expertise and tailored approach enabled a factoring solution aligned with Eldohm’s actual trade flows and financing requirements.

“Through factoring, we can offer our international customers the extended payment terms they need to manage their cash flow effectively when handling large volumes. At the same time, we can pay our suppliers in China earlier in the trade cycle without our own cash flow limiting growth. This creates financial flexibility on both sides of the supply chain and enables us to grow faster together with our partners,” said Pieter van den Bosch of Eldohm.

CRDT and Tradewind Combine Expertise to Deliver the Facility

The transaction was introduced to Tradewind by CRDT, which already supported Eldohm with credit management services. As Eldohm’s financing requirements developed, CRDT helped identify a financing partner with the international experience needed to support its operations.

For trading companies operating across Europe, Asia and the United States, access to appropriate financing can be complicated by differences in legal jurisdictions, corporate structures and the requirements of domestic financing providers.

CRDT’s understanding of Eldohm’s business, combined with Tradewind’s experience in international factoring, contributed to the development of a financing structure suited to the company’s needs.

“International trade requires expertise and a strong network to tailor supply chain finance to the needs of each business,” said Frans van der Hoorn, Managing Director at CRDT.

International Factoring Expertise Supporting Further Expansion

For Tradewind, the transaction demonstrates the importance of structuring financing around the way companies conduct international business.

With decades of trade finance experience and an international network of local teams, Tradewind supports exporters and importers whose financing needs extend beyond traditional domestic banking structures.

Rather than relying solely on Eldohm’s Dutch operations, Tradewind was able to finance receivables through the company’s Hong Kong subsidiary, supporting trade with a US-based buyer.

“Eldohm’s business demonstrates why export factoring needs to reflect the way goods, invoices and payments move across borders. By financing receivables through its Hong Kong entity, we have structured a facility that supports extended customer payment terms while providing the working capital needed for larger orders and further growth in the United States. Our collaboration with CRDT was instrumental in developing a solution aligned with Eldohm’s business,” said Harry Marchal, VP Sales Europe at Tradewind Finance.

The facility provides Eldohm with additional financing capacity to manage increasing order volumes, maintain supplier payments and pursue further international growth. It illustrates how tailored export factoring can improve cash flow and support companies operating across multiple markets.

To learn how Tradewind’s tailor-made trade finance solutions support international growth, visit www.tradewindfinance.com.

About Tradewind Finance

Founded in 2000, Tradewind Finance maintains a global network of offices including Bangladesh, Bulgaria, China, Hong Kong SAR, Hungary, India, Pakistan, Turkey, UAE, and the USA, alongside its headquarters in Germany. Combining financing, credit protection, and collections into one streamlined offering, Tradewind delivers flexible, best-in-class trade finance solutions to exporters and importers worldwide.

View original content to download multimedia:https://www.prnewswire.com/news-releases/tradewind-finance-provides-eur-2-million-export-factoring-facility-to-eldohm-to-support-international-growth-302917926.html

SOURCE Tradewind Finance

Continue Reading

Trending